Could a new immunotherapy stop smoldering myeloma before it becomes active cancer?
Disease control
Recruiting now
This phase II trial compares the anti-cancer activity of teclistamab, an immunotherapy, against the standard combination of lenalidomide and dexamethasone in people with high-risk smoldering multiple myeloma. Smoldering myeloma is a pre-cancerous condition that often progresses t…
Phase: PHASE2 • Sponsor: Irene Ghobrial, MD • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC